Dissecting The Decision: Investigators Discuss the Available Data and Clinical Factors that Shape the Management of Gastrointestinal Cancers
Date and Time: Thursday, January 19, 7:15 PM
Location: San Francisco Marriott Marquis, Golden Gate Ballroom, B2 Level
CME Provider and Supporter(s): This event is organized and accredited by Research To Practice and is supported by educational grants provided by Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Celgene Corporation, Genentech BioOncology, Halozyme Therapeutics, Lilly, Merrimack Pharmaceuticals Inc and Taiho Oncology.
Event Summary: Six investigators will serve as faculty, and prior to the event, Research To Practice (RTP) will recruit five community oncologists to provide challenging cases of patients with advanced colorectal, gastric, pancreatic and hepatocellular cancer. The agenda will be divided into six modules for which cases were ascertained, and the faculty will complete a pre-meeting survey to provide recommendations for each case. All responses will be graphically depicted and interspersed throughout the live event. Attendees will use iPads to complete a similar survey and the results will be juxtaposed with the faculty’s to illustrate any knowledge and practice gaps. Following the case discussions for each module, a faculty member will briefly review emerging research and ongoing trials. Clinicians will also use the iPads to submit their own questions and cases, and the meeting moderator, RTP president Dr. Neil Love, will present specific queries to the panelists to foster additional discussion.
Tanios Bekaii-Saab, MD
Mayo Clinic AZ
Johanna C. Bendell, MD
Sarah Cannon Research Institute
John L. Marshall, MD
Lombardi Comprehensive Cancer Center, Georgetown University
Mary F. Mulcahy, MD
Northwestern University Feindberg School of Medicine
Phlip A. Philip, MD, PhD
Wayne State University
Bert H. O'Neil
Indiana University Simon Cancer Center
Eric Van Cutsem, MD, PhD
University Hospital Gasthuisberg/Leuven
Neil Love, MD—Moderator
Research To Practice
Evolution of the Treatment Algorithm for Carcinoid Syndrome
Date and Time: Thursday, January 19, 7:15 PM
Location: San Francisco Marriott Marquis, Yerba Buena Ballroom, Salon 7
CME Provider and Supporter(s): This event is organized and accredited by prIME Oncology, LLC, and is supported by an educational grant provided by Lexicon Pharmaceuticals, Inc.
Event Summary: Recently, an improved understanding of carcinoid neuroendocrine tumor cell biology has encouraged development of novel targeted therapies. In this symposium, the rationale of inhibiting molecules like tryptophan hydroxylase to suppress peripheral hormone synthesis will be presented. This will facilitate a discussion of results of recent and ongoing clinical trials, such as the TELECAST and TELESTAR trials. Other targeted therapies that can provide control of tumor bulk will also be discussed, with particular focus on the design and results of the NETTER-1 and RADIANT trials. Finally, the faculty will offer insight into how the discussed investigational agents might fit into the future treatment algorithm of carcinoid syndrome.
Emily K. Bergsland, MD
University of California, San Francisco
Matthew H. Kulke, MD- Chair
Dana-Farber Cancer Institute
Thomas O’Dorisio, MD
University of Iowa
Marianne Pavel, MD
Charité University Medicine Berlin
The Dawn of Immunotherapy in Gastric and Colorectal Cancers
Date and Time: Friday, January 20, 7:15 PM
Location: San Francisco Marriott Marquis, Yerba Buena Ballroom, Salon 7, Lower B2 Level
CME Provider and Supporter(s): This event is organized and accredited by prIME Oncology, LLC, and is supported by an educational grant provided by Merck and Co, Inc.
Event Summary:This symposium will describe the molecular basis for immunotherapy in cancers and evidence supporting the theory that gastric cancer and colorectal cancer (CRC) are immunogenic. It will feature a discussion on the need for biomarkers of response to immunotherapy as well as unique aspects of response assessment and adverse event profiles of immunotherapeutic agents. Inherent immunogenicity of MMR-deficient CRC will be described, and recent and ongoing trials will be discussed. Strategies to enhance immune responses in gastric cancer and CRC will be highlighted, including combinations of immunotherapeutic agents with each other, as well as combinations with targeted agents or chemotherapy.
Richard Goldberg, MD
West Virginia University
A. Craig Lockhart, MD, MHS
Bert O’Neil, MD
Alan Venook, MD- Chair
University of California San Francisco